Buy One Get One 50% OFF!
Use Code BOGO50 at Checkout!
Buy One Get One 50% OFF!
Use Code BOGO50 at Checkout!
GLP-1R (LY3437943)
The introduction of Retatrutide represents a shift from single and dual-receptor modulation to a triple-receptor mechanism. Recent Phase 3 data highlights distinct efficacy stratifications among the three primary incretin-based agents:
Semaglutide (GLP-1 Only): In the foundational STEP clinical trials, Semaglutide 2.4mg demonstrated a mean body weight reduction of approximately 15-17% over 68 weeks. Its mechanism is primarily limited to appetite suppression via delayed gastric emptying and central satiety signaling.
Tirzepatide (GLP-1 + GIP): As a dual-agonist, Tirzepatide leverages GIP receptor activity to enhance insulin sensitivity and lipid metabolism. The SURMOUNT clinical program consistently observed weight reductions in the 20-22% range, establishing a superior efficacy profile over mono-agonists.
Retatrutide (GLP-1 + GIP + Glucagon): Data from the Phase 3 TRIUMPH-4 trial (released late 2025) indicates that Retatrutide achieves a mean weight reduction of 28.7% at 68 weeks. This substantial increase in efficacy is attributed to the novel inclusion of Glucagon receptor agonism, which promotes increased resting energy expenditure (thermogenesis) alongside the appetite suppression and metabolic improvements seen in earlier generations.
The introduction of Retatrutide represents a shift from single and dual-receptor modulation to a triple-receptor mechanism. Recent Phase 3 data highlights distinct efficacy stratifications among the three primary incretin-based agents:
Semaglutide (GLP-1 Only): In the foundational STEP clinical trials, Semaglutide 2.4mg demonstrated a mean body weight reduction of approximately 15-17% over 68 weeks. Its mechanism is primarily limited to appetite suppression via delayed gastric emptying and central satiety signaling.
Tirzepatide (GLP-1 + GIP): As a dual-agonist, Tirzepatide leverages GIP receptor activity to enhance insulin sensitivity and lipid metabolism. The SURMOUNT clinical program consistently observed weight reductions in the 20-22% range, establishing a superior efficacy profile over mono-agonists.
Retatrutide (GLP-1 + GIP + Glucagon): Data from the Phase 3 TRIUMPH-4 trial (released late 2025) indicates that Retatrutide achieves a mean weight reduction of 28.7% at 68 weeks. This substantial increase in efficacy is attributed to the novel inclusion of Glucagon receptor agonism, which promotes increased resting energy expenditure (thermogenesis) alongside the appetite suppression and metabolic improvements seen in earlier generations.
Tested using RP-HPLC Purity and Identification analysis, reported at 99.986% Purity.
We believe that trust is built on transparency. That’s why we have partnered with Chromate, a leading independent laboratory, to subject every single batch of our peptides to a comprehensive testing regimen.
99.5%+ Purity
100% Sterility
Endotoxin Free
Contaminant-Free
Retatrutide is a synthetic peptide currently under clinical investigation that functions as a single molecule with triple-agonist activity. Unlike mono-agonists (GLP-1 only) or dual-agonists (GLP-1/GIP), Retatrutide is designed to bind to and activate three distinct receptor sites associated with metabolic regulation:
GLP-1 Receptor (Glucagon-Like Peptide-1): Activation of this receptor is associated with delayed gastric emptying and central signaling related to satiety.
GIP Receptor (Glucose-Dependent Insulinotropic Polypeptide): This pathway is investigated for its role in potentiating glucose-dependent insulin secretion and improving lipid metabolism.
GCGR (Glucagon Receptor): The differentiating factor in Retatrutide’s profile is its activity at the glucagon receptor. In clinical models, GCGR agonism is observed to increase energy expenditure (thermogenesis) and promote hepatic lipid oxidation (breakdown of liver fat).
Get Free Shipping when you sign up for our newsletter!
By submitting, you agree to receive marketing and promotions emails.
